Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024)
Spyre Therapeutics (SYRE) reported Preferred Stock Liabilities of $253.4 million for Q1 2024, up 199.69% quarter-over-quarter from $84.6 million in Q4 2023.
Spyre Therapeutics (SYRE) Preferred Stock Liabilities (2015 - 2024) Analysis & Trends
Spyre Therapeutics has reported Preferred Stock Liabilities for 4 years, with the latest figure at $253.4 million in Q1 2024.
- For the quarter ending Q1 2024, Preferred Stock Liabilities changed N/A year-over-year to $253.4 million; the trailing twelve-month figure through Mar 2024 stood at $253.4 million (changed N/A YoY), and the FY2023 full-year result was $84.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q1 2024 stood at $253.4 million, up from $84.6 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $387.1 million in Q3 2023, with the low at $84.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Spyre Therapeutics | 6.35 Bn | 6.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 253.41 Mn |
| Dec 31, 2023 | 84.56 Mn |
| Sep 30, 2023 | 387.11 Mn |
| Jun 30, 2023 | 197.32 Mn |
| Mar 31, 2016 | 13.57 Mn |
| Dec 31, 2015 | 44.74 Mn |